Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412835 | 0.82 | MEN1 (0.36) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL15438050 | 0.82 | MGAM (0.39) | FAAHLMNAMMP1MMP2MMP3 | |
| SCHEMBL12863876 | 0.78 | ALDH1A1 (0.46) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL7557509 | 0.77 | MMP1 (0.33) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL9517691 | 0.77 | — | — | |
| SCHEMBL15438051 | 0.77 | MMP1 (0.34) | FAAHLMNAMMP1MMP2MMP3 | |
| SCHEMBL14693780 | 0.77 | ALDH1A1 (0.33) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL17860691 | 0.75 | LMNA (0.37) | LMNA | |
| SCHEMBL17878556 | 0.75 | CA1 (0.40) | LMNAMMP1MMP2MMP3MMP9 | |
| SCHEMBL24201024 | 0.75 | MMP1 (0.34) | FAAHLMNAMMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | APOTEX INC. (CA) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351537-B2 | Processes for the preparation of lesinurad and intermediates thereof | LSS, SQOR, PGD | FAAH 1422/4885LMNA 252/4885MMP1 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.